We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+68.72%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$123M
AUM Growth
+$25.1M
Cap. Flow
-$18.6M
Cap. Flow %
-15.13%
Top 10 Hldgs %
93.79%
Holding
27
New
4
Increased
7
Reduced
4
Closed
10

Top Buys

1
VIVE
VIVEVE MED INC
VIVE
+$17.3M
2
ALR
Alere Inc
ALR
+$8.63M
3
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$7M
4
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$6.64M
5
QLTI
QLT Inc
QLTI
+$2.99M

Top Sells

1
SCLN
Sciclone Pharmaceuticals Inc
SCLN
+$14.1M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$9.08M
3
FLNA
Filana Therapeutics
FLNA
+$6.21M
4
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$5.34M
5
VCEL icon
Vericel Corp
VCEL
+$2.83M

Sector Composition

1 Healthcare 76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBRA
1
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$29.2M 23.78%
733,718
+96,151
+15% +$1.07M
VIVE
2
DELISTED
VIVEVE MED INC
VIVE
$18.8M 15.31%
+2,600
New +$17.3M
ALR
3
DELISTED
Alere Inc
ALR
$12.4M 10.11%
286,651
+211,651
+282% +$8.63M
QLTI
4
DELISTED
QLT Inc
QLTI
$11.9M 9.71%
5,778,496
+1,999,222
+53% +$2.99M
SCTL
5
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$10.3M 8.44%
1,305,219
+827,252
+173% +$6.64M
CORV
6
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$6.01M 4.9%
+1,918,722
New +$7M
CUTR
7
DELISTED
Cutera, Inc.
CUTR
$4.77M 3.89%
400,000
-38,000
-9% -$422K
VCEL icon
8
Vericel Corp
VCEL
$2.38B
$2.87M 2.34%
1,023,048
-1,226,952
-55% -$2.83M
ALIM
9
DELISTED
Alimera Sciences
ALIM
$2.84M 2.32%
+127,146
New +$2.93M
DRRX
10
DELISTED
DURECT Corp
DRRX
$2.29M 1.87%
164,617
+156,601
+1,954% +$2.57M
CPIX icon
11
Cumberland Pharmaceuticals
CPIX
$102M
$1.62M 1.32%
323,747
+194,949
+151% +$917K
JNP
12
DELISTED
Juniper Pharmaceuticals, Inc. Common Stock
JNP
$966K 0.79%
+173,967
New +$1.15M
VXRT
13
DELISTED
Vaxart
VXRT
$667K 0.54%
31,585
+4,833
+18% +$76.4K
DSCI
14
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$458K 0.37%
98,064
-185,242
-65% -$865K
PCRX icon
15
Pacira BioSciences
PCRX
$1.01B
$51K 0.04%
1,500
-50,657
-97% -$1.98M
AVDL
16
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-128,005
Closed -$1.38M
FLNA
17
Filana Therapeutics
FLNA
$51.2M
– –
-405,411
Closed -$6.21M
VCYT icon
18
Veracyte
VCYT
$4.72B
– –
-186,926
Closed -$940K
VNDA icon
19
Vanda Pharmaceuticals
VNDA
$327M
– –
-811,563
Closed -$9.08M
BSTC
20
DELISTED
BioSpecifics Technologies Corp.
BSTC
– –
-30,000
Closed -$1.2M
SCMP
21
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
– –
-213,860
Closed -$2.35M
SCLN
22
DELISTED
Sciclone Pharmaceuticals Inc
SCLN
– –
-1,082,532
Closed -$14.1M
SGNT
23
DELISTED
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
– –
-356,307
Closed -$5.34M

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2016 Portfolio in Review

As of Q3 2016, Stonepine Capital Management held 27 positions worth $123M, up 26% from $97.5M the previous quarter. Its ten largest holdings account for 94% of the portfolio.

Stonepine Capital Management withdrew a net $18.6M in Q3 2016, closing 10 positions and reducing 4 holdings. Its most notable exit was Sciclone Pharmaceuticals Inc, an estimated $14.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, up from 63% a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in VIVEVE MED INC worth $18.8M.

  • Stonepine Capital Management's largest Q3 2016 buy was VIVEVE MED INC: 2,600 shares worth $18.8M.
  • Stonepine Capital Management added most to Alere Inc in Q3 2016, an estimated $8.63M increase.
  • Stonepine Capital Management's biggest Q3 2016 reduction was Vericel Corp, cutting an estimated $2.83M.
  • Stonepine Capital Management fully exited Sciclone Pharmaceuticals Inc in Q3 2016, selling an estimated $14.1M.
  • Stonepine Capital Management's ten largest holdings make up 94% of its $123M portfolio in Q3 2016.
  • Stonepine Capital Management opened 4 new positions and closed 10 in Q3 2016.
  • Stonepine Capital Management's portfolio value rose 26% quarter-over-quarter to $123M.

Based on Stonepine Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.